RBPJL

Across TCGA pan-cancer cohorts, RBPJL mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated RBPJL data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RBPJL mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RBPJL expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC are the cancer types where RBPJL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.603	0.226	.003	22	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

RBPJL–PDAC (OS)

Open the PDAC breakdown →